On Nov 05, major Wall Street analysts update their ratings for $Cardinal Health (CAH.US)$, with price targets ranging from $124 to $139.
Morgan Stanley analyst Erin Wright maintains with a buy rating, and maintains the target price at $127.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $133.
UBS analyst Kevin Caliendo maintains with a buy rating, and adjusts the target price from $134 to $139.
Deutsche Bank analyst George Hill maintains with a hold rating, and adjusts the target price from $119 to $124.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and adjusts the target price from $125 to $130.
Furthermore, according to the comprehensive report, the opinions of $Cardinal Health (CAH.US)$'s main analysts recently are as follows:
The revision in Cardinal Health's FY25 EPS guidance upwards from $7.55-$7.70 to $7.75-$7.90 has been positively received, indicating substantial operational upside in F1Q and a guidance boost, underpinned by widespread strength across core pharmaceutical subsegments.
The company delivered a robust fiscal Q1 report that surpassed expectations. Analysts remain optimistic on the company's fundamental distribution strength within the current economic environment and are encouraged by the company's recent demonstrations of successful execution.
Here are the latest investment ratings and price targets for $Cardinal Health (CAH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
